

Saturday (26.10.2024)	Sunday (27.10.2024)	Monday (28.10.2024)	
<p>08:30-11:00 Working towards harmonization of clinical trial reporting in Hodgkin Lymphoma (Chairs: S. Barrington, S. Borchmann, C. Kobe, W. Plattel, D. Rossi)</p> <p>Separate registration required</p>	<p>08:00-09:30 Pediatric and Adolescent Treatment Concepts (Chairs: J. Friedberg, C. Mauz-Körholz)</p> <ul style="list-style-type: none"> Recent achievements and future goals in Pediatric and Young Adult HL <ul style="list-style-type: none"> COG Perspective (S. Castellino) EuroNET-PHL Perspective (C. Mauz-Körholz) Appropriate endpoints for future trials in Pediatric and Young Adult HL, and opportunities for harmonization (J. Frlertage) <p>Break</p> <p>10:00-11:30 Biology & Microenvironment (Chairs: S. Leppä, M. Shipp)</p> <ul style="list-style-type: none"> Pathogenesis of HL (R. Küppers) Multimodal characterization of cHL (C. Steidl) 	<p>08:00-09:00 Special Situations & Cases (Chairs: A. Fosså, A. Sureda)</p> <ul style="list-style-type: none"> Treatment Approaches in Ressource Constraint Settings (Speaker: O. Balocchi, Discussant: C. Asirwa) HL Richter Transformation (S. Hartmann, M. Hertzberg, O. Al-Sawaf) <p>Break</p> <p>09:15-10:15 NLPHL (Chairs: R. Hoppe, W. Klapper)</p> <ul style="list-style-type: none"> NLPHL: HL, NHL or something else? (S. Hartmann) First-line treatment of NLPHL with HL-directed approaches (D. Eichenauer) Treatment of NLPHL with NHL-directed approaches (G. Collins) <p>Break</p> <p>10:30-12:00 Living Beyond Lymphoma (Chairs: F. van Leeuwen, J. Radford)</p> <ul style="list-style-type: none"> Late consequences of drugs used in the modern era of treatment for HL (to include anthracyclines, bleomycin, checkpoint inhibitors, ADCs) (S. Ansell) Starting Living beyond Lymphoma with HL diagnosis (K. Behringer) Participation in and (cost-)effectiveness of the Dutch HL survivorship care program (A. Nijdam, B. Aleman) 	<p>08:00</p> <p>09:15</p> <p>10:10</p> <p>10:30</p> <p>12:00</p>
<p>Break</p> <p>11:30-13:00 Limited Stages (Chairs: M. André, L. Specht)</p> <ul style="list-style-type: none"> Intro: Treatment concepts in early-stage HL (M. André) Viewpoint: Systemic Therapy only in the future? (R. Advani) Viewpoint: CMT (Is it there to stay?) (J. Yahalom) 	<p>Break</p> <p>12:00-13:30 Satellite Symposium</p>	<p>Break</p> <p>12:30-14:00 Relapsed / Refractory HL (Chairs: P. Armand, C. Moskowitz)</p> <ul style="list-style-type: none"> Updated approach to second-line treatment (A. Moskowitz) Emerging strategies to overcome anti-PD1 resistance (S. Ansell) Implementing radiotherapeutic concepts in rrHL care (C. Baues) 	<p>12:30</p> <p>12:00</p> <p>12:30</p>
<p>Break</p> <p>13:15-14:45 Satellite Symposium</p>	<p>Break</p> <p>14:00-15:30 Older Patients (Chairs: P. Bröckelmann, A. Evens)</p> <ul style="list-style-type: none"> Implementing Frailty Assessment for Treatment Guidance in HL (S. Rutherford) Optimal Use of Targeted Agents to Address Unmet Need in Older HL (G. Collins) 	<p>14:00-14:45 Closing Remarks</p> <ul style="list-style-type: none"> WS Report (S. Barrington, S. Borchmann, C. Kobe, W. Plattel, D. Rossi) Best of ISHL13 (R. Advani) <p>14:45-15:15 Farewell</p>	<p>14:00</p> <p>15:00</p>
<p>Break</p> <p>15:15-17:00 Opening and Award Ceremony Keynote Lecture: Linda Partridge</p>	<p>Break</p> <p>16:00-17:30 Satellite Symposium</p>		<p>16:00</p>
<p>Break</p> <p>17:15-20:00 Poster Session with Welcome Reception</p>	<p>Break</p> <p>18:00-19:30 Advanced Stages (Chairs: A. Herrera, J. Zijlstra)</p> <ul style="list-style-type: none"> Individualized treatment de-escalation Improves overall outcomes (P. Borchmann) Immune-chemotherapy overcomes the need for individualization (J. Friedberg) 		<p>17:15</p> <p>18:00</p>